Search results
Results from the WOW.Com Content Network
Dopamine released at this site inhibits the secretion of prolactin from anterior pituitary gland lactotrophs by binding to dopamine receptor D2. Some antipsychotic drugs block dopamine in the tuberoinfundibular pathway, which can cause an increase in the amount of prolactin in the blood ( hyperprolactinemia ).
The VTA contains 5-HT 1A receptors that exert a biphasic effects on firing, with low doses of 5-HT 1A receptor agonists eliciting an increase in firing rate, and higher doses suppressing activity. The 5-HT 2A receptors expressed on dopaminergic neurons increase activity, while 5-HT 2C receptors elicit a decrease in activity. [ 39 ]
Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. [2] Thus, dopamine receptors are common neurologic drug targets; antipsychotics are often dopamine receptor antagonists while psychostimulants are typically indirect agonists of dopamine receptors.
An addictive drug is defined as a substance that affects the mesolimbic system directly or indirectly by increasing extracellular levels of dopamine. [ 24 ] Common addictive substances such as cocaine , alcohol , and nicotine have been shown to increase extracellular levels of dopamine within the mesolimbic pathway, preferentially within the ...
At the earliest stage, genetic differences that alter the expression of dopamine receptors in the brain can predict whether a person will find stimulants appealing or aversive. [115] Consumption of stimulants produces increases in brain dopamine levels that last from minutes to hours. [104]
D 1 receptor has a high degree of structural homology to another dopamine receptor, D 5, and they both bind similar drugs. [13] As a result, none of the known orthosteric ligands is selective for the D 1 vs. the D 5 receptor, but the benzazepines generally are more selective for the D 1 and D 5 receptors versus the D 2-like family. [12]
Dopamine receptor antagonists can be divided into D 1-like receptor antagonists and D 2-like receptor antagonists. Ecopipam is an example of a D 1 -like receptor antagonist. At low doses, dopamine D 2 and D 3 receptor antagonists can preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby increase dopamine levels and ...
Dopamine receptor D 2, also known as D 2 R, is a protein that, in humans, is encoded by the DRD2 gene.After work from Paul Greengard's lab had suggested that dopamine receptors were the site of action of antipsychotic drugs, several groups, including those of Solomon H. Snyder and Philip Seeman used a radiolabeled antipsychotic drug to identify what is now known as the dopamine D 2 receptor. [5]